RPAM
CTIC

Rhenman & Partners Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Rhenman & Partners Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-300,000
Closed -$966K – 96
2020
Q4 		$966K Buy
+300,000
New +$998K 0.08% 82

Other funds holding CTIC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Rhenman & Partners Asset Management's CTIC Position: Q1 2021 in Review

Rhenman & Partners Asset Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2021, closing a stake of 300,000 shares — an estimated $966K sold.

Rhenman & Partners Asset Management first reported a position in CTIC in Q4 2020 and held it in 1 quarter. The position peaked at $966K in Q4 2020. 55 funds tracked by Wall St. Rank hold CTIC as of Q1 2021.

  • Rhenman & Partners Asset Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2021 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 300,000 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2021, an estimated $966K.
  • Rhenman & Partners Asset Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 1 quarter.
  • Rhenman & Partners Asset Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $966K in Q4 2020.
  • 55 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2021.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2021, filed 14 May 2021.